| Not Yet Recruiting | Comparison of Two Etoposide Initiation Strategies for Severe Hemophagocytic Lymphohistiocytosis NCT07497438 | Assistance Publique - Hôpitaux de Paris | Phase 3 |
| Recruiting | Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma NCT07270835 | The First Affiliated Hospital of Soochow University | Phase 4 |
| Not Yet Recruiting | Segmental Resection Combined With DEP Regimen for EBV-HLH Patients With Intestinal Involvement NCT06131489 | Beijing Friendship Hospital | — |
| Unknown | GTP Regimen in the Treatment of Refractory/Recurrent HLH NCT06038422 | Beijing Friendship Hospital | Phase 3 |
| Not Yet Recruiting | L-DEP Regimen Combined With PD-1 Antibody as Induction Therapy for Epstein-Barr Virus-positive LA-HLH NCT05775705 | Beijing Friendship Hospital | Phase 3 |
| Unknown | Efficacy and Safety of Venetoclax Combined With Dexamethasone and Etoposide in HLH NCT05546060 | Beijing Friendship Hospital | Phase 1 |
| Not Yet Recruiting | L-DEP/DEP Regimen and PD-1 Antibody as a Treatment for Relapse/Refractory EBV-HLH NCT05315336 | Beijing Friendship Hospital | Phase 3 |
| Active Not Recruiting | Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytos NCT04551131 | St. Jude Children's Research Hospital | Phase 1 / Phase 2 |
| Unknown | Chidamide Combines With VP-16 and Methylprednisolone in the Treatment of HLH NCT05137522 | Beijing Friendship Hospital | N/A |
| Unknown | DEP Combine With PD-1 Antibody as an Treatment for EBV-HLH NCT05164978 | Beijing Friendship Hospital | N/A |
| Unknown | A Study of TQ05105 Tablets in Subjects With Hemophagocytic Lymphohistiocytosis（HLH） NCT04326348 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 |
| Unknown | Pegylated Liposomal Doxorubicin as a Induction Therapy for Lymphoma Induced Hemophagocytic Lymphohistiocytosis NCT04077905 | Beijing Friendship Hospital | Phase 3 |
| Unknown | Ruxolitinib as a Salvage Therapy for Hemophagocytic Lymphohistiocytosis NCT04120090 | Beijing Friendship Hospital | Phase 3 |
| Unknown | Etoposide in the First-line Treatment of Adult EBV-HLH NCT03742115 | Beijing Friendship Hospital | Phase 3 |
| Completed | Diagnostic Biomarkers for Adult Hemophagocytic Lymphohistiocytosis in Critically Ill Patients (HEMICU) NCT03510650 | Charite University, Berlin, Germany | — |
| Unknown | DEP-Ru Regimen as a Salvage Therapy for HLH NCT03533790 | Beijing Friendship Hospital | Phase 3 |
| Unknown | Ruxolitinib Combined With Dexamethasone for HLH NCT03795909 | Capital Research Institute of Pediatrics | Phase 1 / Phase 2 |
| Completed | Evaluation of IFNγ and Inflammatory Mediators in Patients With Malignancy-Associated Hemophagocytic Lymphohist NCT03259230 | Swedish Orphan Biovitrum | — |
| Unknown | L-DEP as an Initial Treatment for EBV-HLH NCT02912702 | Beijing Friendship Hospital | Phase 3 |
| Unknown | L-DEP Regimen as a Salvage Therapy for Refractory Epstein Barr Virus-induced Hemophagocytic Lymphohistiocytosi NCT02631109 | Beijing Friendship Hospital | Phase 3 |
| Terminated | Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases NCT02231710 | Bellicum Pharmaceuticals | Phase 1 |
| Unknown | Splenectomy as a Treatment for Patient With Relapsed Haemophagocytic Lymphohistiocytosis of Unknown Etiology NCT02862054 | Beijing Friendship Hospital | Phase 2 / Phase 3 |
| Completed | A Study for Long-term Follow-up of Hemophagocytic Lymphohistiocytosis (HLH) Participants Who Received Treatmen NCT02069899 | Swedish Orphan Biovitrum | Phase 2 / Phase 3 |
| Completed | Bone Marrow Transplant With Abatacept for Non-Malignant Diseases NCT01917708 | Emory University | Phase 1 |
| Completed | Reduced Intensity Conditioning for Hemophagocytic Syndromes or Selected Primary Immune Deficiencies (BMT CTN 1 NCT01998633 | Medical College of Wisconsin | Phase 2 |
| Withdrawn | Tocilizumab and Hemophagocytic Lymphohistiocytosis (HLH) NCT02007239 | Children's Hospital of Philadelphia | Phase 2 |
| Active Not Recruiting | Immune Disorder HSCT Protocol NCT01821781 | Washington University School of Medicine | Phase 2 |
| Active Not Recruiting | Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies NCT01652092 | Masonic Cancer Center, University of Minnesota | N/A |
| Terminated | Pilot Study of Etoposide-based Therapy and Hematopoietic Cell Transplantation for Hemophagocytic Lymphohistioc NCT01547143 | Asan Medical Center | N/A |
| Active Not Recruiting | Administration of Donor T Cells With the Caspase-9 Suicide Gene NCT01494103 | Baylor College of Medicine | Phase 1 |
| Recruiting | Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford NCT01793168 | Sanford Health | — |
| Completed | Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis NCT01104025 | Children's Hospital Medical Center, Cincinnati | Phase 2 |
| Completed | Treatment Protocol for Hemophagocytic Lymphohistiocytosis 2004 NCT00426101 | Karolinska University Hospital | Phase 3 |
| Completed | Stem Cell Transplant for Immunologic or Histiocytic Disorders NCT00176865 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Terminated | T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic Disorders NCT00176826 | Masonic Cancer Center, University of Minnesota | Phase 2 / Phase 3 |
| Unknown | Pilot Study of Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients With Life Threatening Hemop NCT00006056 | Fairview University Medical Center | N/A |
| Terminated | Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies NCT00006054 | Fairview University Medical Center | N/A |